While all 4 target genes predicted reduced OS and PFI in LGG patients, both FANCB and TOP2A showed a protective role in the risk score model, indicating the controversial effect of FANCB and TOP2A in glioma patients. This evidence concerns the gene FANCB and central nervous system cancer.